PLoS ONE · 2019 · 99 citations · 55 references
Life SciencesNeurosciencePharmacologyEpilepsyEpileptologyMitochondrial BiologyMetabolic EpilepsiesMitochondrial BioenergeticsMitochondrial DiseaseMitochondrial DisordersMitochondrial DysfunctionMitochondrial Neurological DisordersGlutathione Peroxidase 4Glutathione Peroxidase ActivityGlutathione ReductionLipoxygenase PathwayMitochondrial Disease PathologyMitochondrial Iron Metabolism
BACKGROUND: Mitochondrial disease is a family of genetic disorders characterized by defects in the generation and regulation of energy. Epilepsy is a common symptom of mitochondrial disease, and in the vast majority of cases, refractory to commonly used antiepileptic drugs. Ferroptosis is a recently-described form of iron- and lipid-dependent regulated cell death associated with glutathione depletion and production of lipid peroxides by lipoxygenase enzymes. Activation of the ferroptosis pathway has been implicated in a growing number of disorders, including epilepsy. Given that ferroptosis is regulated by balancing the activities of glutathione peroxidase-4 (GPX4) and 15-lipoxygenase (15-LO), targeting these enzymes may provide a rational therapeutic strategy to modulate seizure. The clinical-stage therapeutic vatiquinone (EPI-743, α-tocotrienol quinone) was reported to reduce seizure frequency and associated morbidity in children with the mitochondrial disorder pontocerebellar hypoplasia type 6. We sought to elucidate the molecular mechanism of EPI-743 and explore the potential of targeting 15-LO to treat additional mitochondrial disease-associated epilepsies. METHODS: Primary fibroblasts and B-lymphocytes derived from patients with mitochondrial disease-associated epilepsy were cultured under standardized conditions. Ferroptosis was induced by treatment with the irreversible GPX4 inhibitor RSL3 or a combination of pharmacological glutathione depletion and excess iron. EPI-743 was co-administered and endpoints, including cell viability and 15-LO-dependent lipid oxidation, were measured. RESULTS: EPI-743 potently prevented ferroptosis in patient cells representing five distinct pediatric disease syndromes with associated epilepsy. Cytoprotection was preceded by a dose-dependent decrease in general lipid oxidation and the specific 15-LO product 15-hydroxyeicosatetraenoic acid (15-HETE). CONCLUSIONS: These findings support the continued clinical evaluation of EPI-743 as a therapeutic agent for PCH6 and other mitochondrial diseases with associated epilepsy.
55
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Scott J. Dixon, Kathryn M. Lemberg, Michael R. Lamprecht et al. · Cell · 2012 · 18.1K citations · Full text
Regulation of Ferroptotic Cancer Cell Death by GPX4
Wan Seok Yang, Rohitha Sriramaratnam, Matthew Welsch et al. · Cell · 2014 · 7.5K citations · Full text
ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition
Sebastian Doll, Bettina Proneth, Yulia Y. Tyurina et al. · Nature Chemical Biology · 2016 · 4.1K citations · Full text
Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis
Valerian E. Kagan, Gaowei Mao, Feng Qu et al. · Nature Chemical Biology · 2016 · 2.8K citations · Full text